T1	Participants 131 147	prostate cancer.
T2	Participants 251 290	patients with high-risk prostate cancer
T3	Participants 314 382	Between January 2003 and December 2007, 168 patients were randomized
T4	Participants 622 695	All patients had undergone a 9-month course of total androgen deprivation
T5	Participants 1519 1551	conventional fractionation group
T6	Participants 1751 1786	conventional fractionation schedule
